ROSSI, Stefania
 Distribuzione geografica
Continente #
NA - Nord America 946
EU - Europa 376
AS - Asia 261
OC - Oceania 2
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.587
Nazione #
US - Stati Uniti d'America 945
CN - Cina 181
UA - Ucraina 131
DE - Germania 78
GB - Regno Unito 54
HK - Hong Kong 44
IT - Italia 42
FI - Finlandia 38
IN - India 21
IE - Irlanda 19
FR - Francia 6
RU - Federazione Russa 6
SG - Singapore 4
IR - Iran 3
AU - Australia 2
BD - Bangladesh 2
JP - Giappone 2
EU - Europa 1
IM - Isola di Man 1
KG - Kirghizistan 1
MU - Mauritius 1
PA - Panama 1
PK - Pakistan 1
SE - Svezia 1
TJ - Tagikistan 1
VN - Vietnam 1
Totale 1.587
Città #
Fairfield 129
Woodbridge 122
Jacksonville 96
Houston 77
Seattle 63
Cambridge 57
Ashburn 56
Ann Arbor 55
Wilmington 49
Hong Kong 44
Princeton 38
Beijing 36
Lancaster 36
Chandler 32
Nanjing 32
New York 23
Dearborn 20
Dublin 19
Helsinki 19
Brescia 16
Hebei 16
Des Moines 13
Jinan 12
Shenyang 12
Nanchang 10
Taizhou 9
Tianjin 9
Changsha 8
San Diego 7
San Mateo 7
Shanghai 6
Verona 6
Milan 5
Ningbo 5
Hangzhou 4
Leawood 4
San Francisco 4
Guangzhou 3
Haikou 3
Zhengzhou 3
Ardabil 2
Dhaka 2
Fuzhou 2
Jiaxing 2
Kilburn 2
Kunming 2
Lanzhou 2
London 2
Norwalk 2
Treviglio 2
Bangalore 1
Berlin 1
Bishkek 1
Bollate 1
Douglas 1
Dushanbe 1
Frankfurt am Main 1
Guiyang 1
Gunzenhausen 1
Hanover 1
Islamabad 1
Latina 1
Melbourne 1
Middlesbrough 1
Monmouth Junction 1
Nürnberg 1
Orange 1
Prescot 1
Saigon 1
Secaucus 1
Southwark 1
Sydney 1
Taurianova 1
Tokyo 1
Wandsworth 1
Washington 1
Xian 1
Totale 1.212
Nome #
Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma 139
Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems 129
Caveolin 1 is a marker of poor differentiation in Rhabdomyosarcoma 119
CAVEOLIN-1 IS A MARKER OF POOR DIFFERENTIATION IN RHABDOMYOSARCOMA 109
Point mutated Caveolin-3 form (P104L) impairs myoblast differentiation via Akt and p38 signalling reduction, leading to an immature cell signature 108
The cytosolic sialidase Neu2 is degraded by autophagy during myoblast atrophy. 107
Phenotypic behavior of C2C12 myoblasts upon expression of the dystrophy-related caveolin-3 P104L and TFT mutants 101
Rhabdomyosarcomas: an overview on the experimental animal models. 99
Defective myogenic differentiation of human rhabdomyosarcoma cells is characterized by sialidase Neu2 loss of expression. 98
Caveolins in rhabdomyosarcoma 92
The enzymatic activity of sialidase Neu2 is inversely regulated during in vitro myoblast hypertrophy and atrophy. 90
The cytosolic sialidase Neu2 is substrate of degradation by autophagy during myoblast atrophy 69
DORSOMORPHIN, A SELECTIVE INHIBITOR OF SMAD1/5/8 PHOSPHORYLATION, IS A POTENT ENHANCER OF MYOBLAST DIFFERENTIATION 65
CAVEOLIN-1 PROMOTES PROLIFERATION AND CONFERS RESISTANCE TO OXIDATIVE STRESS-INDUCED CELL DEATH IN RHABDOMYOSARCOMA CELLS 61
Developmental expression of the sialidase Neu2 ortholog gene in zebrafish and characterization of the knock-down model. 59
The expression of Caveolin-3 and its related Limb Girdle Muscular Dystrophy 1-c mutants in myoblasts: physiological and pathological aspects 58
FUNCTIONAL ANTAGONISM BETWEEN P38 AND MYOSTATIN PATHWAYS IN RHABDOMYOSARCOMA CELLS 52
Differentiation of human rhabdomyosarcoma RD cells is regulated by reciprocal, functional interactions between myostatin, p38 and ERK signalling pathways 51
L6E9 Myoblasts Are Deficient of Myostatin and Additional TGF-βMembers Are Candidates to Developmentally Control Their FiberFormation 49
Totale 1.655
Categoria #
all - tutte 6.693
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.693


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019100 0 0 0 0 0 0 0 0 0 0 40 60
2019/2020478 59 13 17 61 27 53 57 49 43 56 17 26
2020/2021250 7 29 11 25 9 27 4 30 40 22 38 8
2021/2022168 5 38 2 1 0 3 11 7 3 31 29 38
2022/2023127 19 3 8 3 6 31 0 13 20 0 9 15
2023/2024143 10 6 22 7 7 26 10 4 48 1 2 0
Totale 1.655